Welcome to the 2014 Annual Report

Our journey forward

At Shire we have a clear and focused strategy to become a leading global biotech delivering innovative medicines to patients with rare diseases and other specialty conditions.

Download the full PDF

We work together as one to excel across four key strategic drivers:

Chairman’s review

At Shire we focus on people. Those that work for us, partner with us, invest in our strategy and, above all, those who depend on the medicines we make every day. Our purpose is to help people with life-altering conditions lead better lives. We ask the questions that are raised by rare and specialty diseases and pursue new possibilities through thoughtful and innovative science.

We have a strong,
independent future.
And we’re passionate
about building it.

Download the PDF
Susan Kilsby

Susan Kilsby


Chief Executive Officer’s review

In 2014 we delivered record sales and profitability, and continued to strengthen our pipeline of important medicines to enable people with life altering conditions to lead better lives.

Watch the Video Download the PDF
Dr Flemming Ornskov

Dr. Flemming Ornskov

Chief Executive Officer


Shire delivered record sales and earnings in 2014 and is well positioned for continued growth and success.

Our business units

Ophthalmics, Neuroscience, GI and Internal Medicine, Rare diseases.
  • Product sales

  • People

  • Investment in
    Non GAAP R&D1

  • Countries with

Read more
1This is a Non GAAP financial measure. For reconciliation to US GAAP please see page 166 of the Annual Report.

Strategy and business model

We focus on researching, developing and marketing innovative medicines that have the potiential to transform the lives of people around the world with rare and other specialized conditions.

Product sales; Percent CAGR

2013: five billion dollars in-line. 2020: Seven billion dollars in-line, three billion dollars existing pipeline, ten billion-plus dollars upside.

To guide and motivate us on our journey we seek to achieve product sales of $10 billion by 2020 (10 x 20):

  • In-line: $7 billion expected from on-market products1
  • Pipeline: $3 billion expected from existing pipeline1
  • Upside: NPS Pharma, Lumena, Fibrotech, BIKAM, CINRYZE new uses, early stage pipeline and future business development provide additional upside to 10 x 20
1 Shire announced its 10 x 20 aspiration on June 23, 2014 and seeks to achieve 2020 product sales of $10 billion from its In-line and Pipeline portfolio as at May 2014.
Read more
* $5bn represents sales from continuing operations.